TOKYO, Japan, 4th July 2022 – EPS International Holdings Co., Ltd. (“EPS International” hereafter) and EP-Sogo Co., Ltd. (“EP-SOGO” hereafter), both of which are wholly owned subsidiaries of EPS Holdings, Inc., announced that EPS International and EP-SOGO have agreed to transfer all shares of Total Trial Management Consulting Co., Ltd. ("TTMC" hereafter), a wholly owned subsidiary of EPS International and operating a SMO business in Taiwan, to EP-SOGO, one of largest SMOs in Japan.

1. Purpose of the Reorganization

Last year, the EPS Group celebrated its 30th anniversary and conducted a management buyout (MBO), moving toward "the New EPS". The reorganization of the domestic CRO business was completed on schedule as of 1st July 2022, and this reorganization is related to the overseas business following the domestic business.

TTMC has been providing localized services as an SMO in Taiwan for more than 20 years since its establishment. Until now, TTMC has been part of our overseas business belonging to the Global Research segment and operated as a subsidiary of EPS International.

EP-SOGO supports clinical trials and post-marketing clinical trials conducted by medical institutions for pharmaceuticals, medical devices, and regenerative medicine products as the industry's leading SMO in Japan. At this time, EP-SOGO has decided to acquire TTMC as a direct subsidiary in order to further develop TTMC capabilities by sharing the experience and know-how of EP-SOGO and creating synergistic effects.
In the domestic SMO business, for example, the business environment surrounding SMOs has been changing dramatically, as DCT (Decentralized Clinical Trials) have begun to spread and the need for remote access to medical records is rapidly increasing due to the COVID-19 pandemic. In response to these changes in the environment, EP-SOGO has been actively creating solutions, such as the development of the next-generation Remote SDV*1 system "SYNOV-R". In Taiwan, where the healthcare system and environment are much closer to those of Japan than in other countries, EP-SOGO is expected to be able to utilize its expertise in the SMO business.

Overview of Transferred Company

*As of 1st July 2022

2. Schedule

After discussing the details of this share transfer, EP-SOGO and EPS International will conclude a share transfer agreement, and the shares are scheduled to be transferred in early August 2022.

*1. Remote SDV: A method of directly accessing source documents such as medical records and worksheets from outside a medical institution (remote location) and verifying the submitted data against the records on the source documents.

[About EPS group]
Since its establishment in 1991 as one of pioneering CROs, EPS Group has been a Healthcare Solution Provider to pharmaceutical companies, medical device manufacturers, hospitals and clinics, and academia with various solutions from development to marketing, sales, consultation covering Asia centered in China and new values created in big data & AI, regenerative medicine, etc. The strength of EPS Group lies in the fact that it has the greatest presence in Japan. In Asia, the company has multiple overseas offices and has focused particularly on solidifying its sites in the respective Asian countries, providing clinical development support services as well as SMO services.

[Contact]
Corporate Communications Office
EPS Holdings, Inc.
Email: